Produktname:5-Bromo-2-hydroxybenzaldehyde
IUPAC Name:5-bromo-2-hydroxybenzaldehyde
- CAS：1761-61-1
- Molekulare Formel：C7H5BrO2
- Reinheit：95+%
- Katalognummer：CM101055
- Molekulargewicht：201.02
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:1761-61-1
- Molekulare Formel:C7H5BrO2
- Schmelzpunkt:-
- SMILES-Code:O=CC1=CC(Br)=CC=C1O
- Dichte:
- Katalognummer:CM101055
- Molekulargewicht:201.02
- Siedepunkt:247.3°C at 760 mmHg
- Mdl-Nr.:MFCD00003330
- Lagerung:Keep in Inert atmosphere, store at 2-8°C.
Category Infos
- Benzenes
- Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.
Column Infos
- Carbonyl Compounds
- In organic chemistry, a carbonyl group is a functional group with the formula C=O, composed of a carbon atom double-bonded to an oxygen atom, and it is divalent at the C atom. It is common to several classes of organic compounds (such as aldehydes, ketones and carboxylic acids), as part of many larger functional groups. A compound containing a carbonyl group is often referred to as a carbonyl compound.
- NMD670
- NMD Pharma A/S announces that it has dosed the first generalized myasthenia gravis patient in a Phase 2b clinical trial of NMD670, after receiving FDA IND clearance in March 2024 to conduct the study.
NMD670 is a first-in-class small molecule inhibitor of the skeletal muscle specific chloride ion channel (CIC-1). NMD Pharma has demonstrated that CIC-1 inhibition enhances weakened neuromuscular transmission and restores skeletal muscle function, and this novel treatment approach has demonstrated compelling preclinical and clinical data in animal models of myasthenia gravis, spinal muscular atrophy and a range of other neuromuscular disorders. NMD670 has also been granted orphan-drug designation by the U.S. FDA for treatment of gMG.
Suche 
+86 21 5895 0110 
